This target was of particular interest, first due to its role in MAPK signaling, a crucial pathway in thyroid cancer, and in addition, our group had previously identified SPRY4 as a novel candidate susceptibility gene for familial nonmedullary thyroid cancer (FNMTC) [45]. This evidence concerns the gene SPRY4 and familial papillary or follicular thyroid carcinoma.